Journal of Biological Chemistry · 2015 · 37 citations · 46 references
Life SciencesBiochemistryCardiologyCellular MetabolismMetabolismSignal TransductionCardiovascular Molecular PhysiologyFatty Acid BiosynthesisFatty Acid MetabolismFatty Acid SynthesisHeart FailureCardiac Energetic MetabolismFatty Acid Synthase InhibitionFatty Acid Synthase MechanismHeart Failure Molecular MechanismsMetabolic Cardiac DysfunctionMetabolic ModulationMyocardial MetabolismPalmitate Synthesis
Impairment of myocardial fatty acid substrate metabolism is characteristic of late-stage heart failure and has limited treatment options. Here, we investigated whether inhibition of G-protein-coupled receptor kinase 2 (GRK2) could counteract the disturbed substrate metabolism of late-stage heart failure. The heart failure-like substrate metabolism was reproduced in a novel transgenic model of myocardium-specific expression of fatty acid synthase (FASN), the major palmitate-synthesizing enzyme. The increased fatty acid utilization of FASN transgenic neonatal cardiomyocytes rapidly switched to a heart failure phenotype in an adult-like lipogenic milieu. Similarly, adult FASN transgenic mice developed signs of heart failure. The development of disturbed substrate utilization of FASN transgenic cardiomyocytes and signs of heart failure were retarded by the transgenic expression of GRKInh, a peptide inhibitor of GRK2. Cardioprotective GRK2 inhibition required an intact ERK axis, which blunted the induction of cardiotoxic transcripts, in part by enhanced serine 273 phosphorylation of Pparg (peroxisome proliferator-activated receptor γ). Conversely, the dual-specific GRK2 and ERK cascade inhibitor, RKIP (Raf kinase inhibitor protein), triggered dysfunctional cardiomyocyte energetics and the expression of heart failure-promoting Pparg-regulated genes. Thus, GRK2 inhibition is a novel approach that targets the dysfunctional substrate metabolism of the failing heart.
46
Steven A. Kliewer, Scott S. Sundseth, Stacey A. Jones et al. · Proceedings of the National Academy of Sciences · 1997 · 2.2K citations · Full text
Inhibition of Adipogenesis Through MAP Kinase-Mediated Phosphorylation of PPARγ
Erding Hu, Jae Bum Kim, Pasha Sarraf et al. · Science · 1996 · 1K citations
Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγ by Cdk5
Jang Hyun Choi, Alexander S. Banks, Jennifer L. Estall et al. · Nature · 2010 · 881 citations
Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs
Changsung Kim, Johnson Wong, Jianyan Wen et al. · Nature · 2013 · 523 citations · Full text
Medicine, Cardiology, Genetics +8